Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | MAPT | P10636 | 7/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | VCP | P55072 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8976661 | 0.87 | ALDH1A1 (0.77) | EPAS1ALDH1A1MAPTRXFP1MEN1 | |
| SCHEMBL30431609 | 0.84 | ALDH1A1 (0.73) | EPAS1ALDH1A1MAPTRXFP1MEN1 | |
| SCHEMBL28616516 | 0.84 | ALDH1A1 (0.73) | EPAS1ALDH1A1MAPTRXFP1MEN1 | |
| SCHEMBL28635059 | 0.81 | MAPT (0.74) | EPAS1ALDH1A1MAPTRXFP1MEN1 | |
| SCHEMBL13381588 | 0.79 | MAPT (0.71) | EPAS1ALDH1A1MAPTRXFP1MEN1 | |
| SCHEMBL28620603 | 0.78 | ALDH1A1 (0.63) | EPAS1ALDH1A1MAPTRXFP1MEN1 | |
| SCHEMBL30430973 | 0.78 | ALDH1A1 (0.63) | EPAS1ALDH1A1MAPTRXFP1MEN1 | |
| SCHEMBL10930533 | 0.77 | LMNA (0.77) | EPAS1ALDH1A1MAPTRXFP1MEN1 | |
| SCHEMBL30431601 | 0.75 | EPAS1 (0.71) | EPAS1ALDH1A1MAPTRXFP1MEN1 | |
| SCHEMBL28619635 | 0.75 | EPAS1 (0.71) | EPAS1ALDH1A1MAPTRXFP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332497-B2 | As inhibitors of protein kinases | ABBOTT GMBH & CO KG (DE) | 2008-02-19 | — | — | US | disclosed |
| EP-1379528-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH (DE) | 2005-12-07 | — | — | EP | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1379528-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GmbH (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-01-08 | — | — | US | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002076986-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, UGT1A1, ABCB1 | EPAS1 2745/4885ALDH1A1 81/4885MAPT 3448/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | EPAS1 2854/4885ALDH1A1 99/4885MAPT 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.